Next Article in Journal
Fractional Flow Reserve Derived from Coronary Computed Tomography Angiography Safely Defers Invasive Coronary Angiography in Patients with Stable Coronary Artery Disease
Next Article in Special Issue
FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy
Previous Article in Journal
First Multi-Center All-Comers Study for the Aquablation Procedure
Previous Article in Special Issue
Sex-Sparing Robot-Assisted Radical Cystectomy with Intracorporeal Padua Ileal Neobladder in Female: Surgical Technique, Perioperative, Oncologic and Functional Outcomes
Open AccessArticle

A Multiplex Test Assessing MiR663ame and VIMme in Urine Accurately Discriminates Bladder Cancer from Inflammatory Conditions

1
Cancer Biology and Epigenetics Group—Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), and Porto Comprehensive Cancer Center (P.CCC), Maimonides Biomedical Research Institute of Cordoba, 14004 Cordoba, Spain
2
Department of Urology, University Hospital of Reina Sofia, Maimonides Biomedical Research Institute of Cordoba, 14004 Cordoba, Spain
3
Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal
4
Department of Urology, Portuguese Oncology Institute of Porto (IPO-Porto), 4200-072 Porto, Portugal
5
Department of Epidemiology, Portuguese Oncology Institute of Porto (IPO Porto) & Cancer Epidemiology Group—Research Center (CI-IPOP), 4200-072 Porto, Portugal
6
Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS)—University of Porto, 4050-313 Porto, Portugal
7
Department of Surgery and Pathology, Faculty of Medicine, University of Cordoba, 14071 Cordoba, Spain
8
Champalimaud Clinical Center, 1400-038 Lisbon, Portugal
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(2), 605; https://doi.org/10.3390/jcm9020605
Received: 28 January 2020 / Revised: 14 February 2020 / Accepted: 18 February 2020 / Published: 24 February 2020
(This article belongs to the Special Issue Outcomes and Therapeutic Management of Bladder Cancer)
Bladder cancer (BlCa) is a common malignancy with significant morbidity and mortality. Current diagnostic methods are invasive and costly, showing the need for newer biomarkers. Although several epigenetic-based biomarkers have been proposed, their ability to discriminate BlCa from common benign conditions of the urinary tract, especially inflammatory diseases, has not been adequately explored. Herein, we sought to determine whether VIMme and miR663ame might accurately discriminate those two conditions, using a multiplex test. Performance of VIMme and miR663ame in tissue samples and urines in testing set confirmed previous results (96.3% sensitivity, 88.2% specificity, area under de curve (AUC) 0.98 and 92.6% sensitivity, 75% specificity, AUC 0.83, respectively). In the validation sets, VIMme-miR663ame multiplex test in urine discriminated BlCa patients from healthy donors or patients with inflammatory conditions, with 87% sensitivity, 86% specificity and 80% sensitivity, 75% specificity, respectively. Furthermore, positive likelihood ratio (LR) of 2.41 and negative LR of 0.21 were also disclosed. Compared to urinary cytology, VIMme-miR663ame multiplex panel correctly detected 87% of the analysed cases, whereas cytology only forecasted 41%. Furthermore, high miR663ame independently predicted worse clinical outcome, especially in patients with invasive BlCa. We concluded that the implementation of this panel might better stratify patients for confirmatory, invasive examinations, ultimately improving the cost-effectiveness of BlCa diagnosis and management. Moreover, miR663ame analysis might provide relevant information for patient monitoring, identifying patients at higher risk for cancer progression. View Full-Text
Keywords: bladder cancer; methylation; biomarkers bladder cancer; methylation; biomarkers
Show Figures

Figure 1

MDPI and ACS Style

Monteiro-Reis, S.; Blanca, A.; Tedim-Moreira, J.; Carneiro, I.; Montezuma, D.; Monteiro, P.; Oliveira, J.; Antunes, L.; Henrique, R.; Lopez-Beltran, A.; Jerónimo, C. A Multiplex Test Assessing MiR663ame and VIMme in Urine Accurately Discriminates Bladder Cancer from Inflammatory Conditions. J. Clin. Med. 2020, 9, 605. https://doi.org/10.3390/jcm9020605

AMA Style

Monteiro-Reis S, Blanca A, Tedim-Moreira J, Carneiro I, Montezuma D, Monteiro P, Oliveira J, Antunes L, Henrique R, Lopez-Beltran A, Jerónimo C. A Multiplex Test Assessing MiR663ame and VIMme in Urine Accurately Discriminates Bladder Cancer from Inflammatory Conditions. Journal of Clinical Medicine. 2020; 9(2):605. https://doi.org/10.3390/jcm9020605

Chicago/Turabian Style

Monteiro-Reis, Sara; Blanca, Ana; Tedim-Moreira, Joana; Carneiro, Isa; Montezuma, Diana; Monteiro, Paula; Oliveira, Jorge; Antunes, Luís; Henrique, Rui; Lopez-Beltran, António; Jerónimo, Carmen. 2020. "A Multiplex Test Assessing MiR663ame and VIMme in Urine Accurately Discriminates Bladder Cancer from Inflammatory Conditions" J. Clin. Med. 9, no. 2: 605. https://doi.org/10.3390/jcm9020605

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop